Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. The company is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHV
Previous Symbol
CUSIP68230A10
Phone604-736-3678
Debt
Debt-to-Equity RatioN/A
Current Ratio4.56
Quick Ratio4.56
Price-To-Earnings
Trailing P/E Ratio-0.08
Forward P/E Ratio-0.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.06 million
Price / Sales2.38
Cash FlowN/A
Price / CashN/A
Book Value$2.11 per share
Price / Book0.85
Profitability
EPS (Most Recent Fiscal Year)($22.10)
Net Income$-10,580,000.00
Net MarginsN/A
Return on Equity-114.68%
Return on Assets-93.51%
Miscellaneous
Employees13
Outstanding Shares6,720,000
Market Cap$11.76 million
OptionableNot Optionable
Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions
What is Achieve Life Sciences' stock symbol?
Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."
When did Achieve Life Sciences' stock split? How did Achieve Life Sciences' stock split work?
Achieve Life Sciences shares reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 10 shares after the split.
How were Achieve Life Sciences' earnings last quarter?
Achieve Life Sciences Inc (NASDAQ:ACHV) issued its quarterly earnings data on Thursday, November, 8th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.28) by $0.57. View Achieve Life Sciences' Earnings History.
When is Achieve Life Sciences' next earnings date?
What price target have analysts set for ACHV?
1 brokers have issued 12 month target prices for Achieve Life Sciences' shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Achieve Life Sciences' share price to reach $12.00 in the next year. This suggests a possible upside of 570.4% from the stock's current price. View Analyst Price Targets for Achieve Life Sciences.
What is the consensus analysts' recommendation for Achieve Life Sciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Achieve Life Sciences.
Has Achieve Life Sciences been receiving favorable news coverage?
News stories about ACHV stock have been trending very positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Achieve Life Sciences earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Achieve Life Sciences' key competitors?
Who are Achieve Life Sciences' key executives?
Achieve Life Sciences' management team includes the folowing people:
- Dr. Richard A. B. Stewart, Chairman & CEO (Age 59)
- Dr. Anthony Clarke, Pres, Chief Scientific Officer & Director (Age 62)
- Mr. John A. Bencich, Exec. VP, CFO & COO (Age 41)
- Dr. Cindy Jacobs, Exec. VP & Chief Medical Officer (Age 60)
Who are Achieve Life Sciences' major shareholders?
Achieve Life Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.67%), Sio Capital Management LLC (3.65%), Dimensional Fund Advisors LP (0.81%) and Worth Venture Partners LLC (0.70%). View Institutional Ownership Trends for Achieve Life Sciences.
Which major investors are buying Achieve Life Sciences stock?
How do I buy shares of Achieve Life Sciences?
Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achieve Life Sciences' stock price today?
One share of ACHV stock can currently be purchased for approximately $1.79.
How big of a company is Achieve Life Sciences?
Achieve Life Sciences has a market capitalization of $11.76 million and generates $5.06 million in revenue each year. The biopharmaceutical company earns $-10,580,000.00 in net income (profit) each year or ($22.10) on an earnings per share basis. Achieve Life Sciences employs 13 workers across the globe.
What is Achieve Life Sciences' official website?
How can I contact Achieve Life Sciences?
Achieve Life Sciences' mailing address is 1001 W. BROADWAY SUITE 400, VANCOUVER BC, V6H 4B1. The biopharmaceutical company can be reached via phone at 604-736-3678 or via email at [email protected]
MarketBeat Community Rating for Achieve Life Sciences (NASDAQ ACHV)
MarketBeat's community ratings are surveys of what our community members think about Achieve Life Sciences and other stocks. Vote "Outperform" if you believe ACHV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHV will underperform the S&P 500 over the long term. You may vote once every thirty days.
